Life AI
By Life AIInfiniteLife addresses the trillion dollar pharmaceutical market, aiming to make drug discovery 10x cheaper and 10x faster, by combining a biology wet-lab with a GPU-powered “curated data centre” and modern AI technologies, including development of proprietary foundation models.
- Stage
- Idea
- Industries
- Healthcare
- Deployment
- Hybrid
Why it is worth it
While most of the aforementioned AI platforms, such as TxGemma, position themselves as generic LLM-based foundation models, InfiniteLife develops its proprietary foundation models as vertical specific foundation models for drug discovery, mainly focusing on Central Nervous Systems (CNS) diseases, such as Parkinson’s and Stroke. Even with CNS-focused AI-based drug discovery companies, the space is too big to have head-to-head competitors. Most likely, each company will focus on a very specific topic or in a very specific direction to train a specific proprietary foundation model.
- We shamelessly copy this statement from Google’s TxGemma website (https://developers.googleblog.com/en/introducing-txgemma-open-models-improving-therapeutics-development/) because the problem we are solving is a wellknown problem.
- “Developing a new therapeutic is risky, notoriously slow, and can cost billions of dollars. 90% of drug candidates fail beyond phase 1 trials.”
- We emphasize one more time: While most of the aforementioned AI platforms, such as TxGemma, position themselves as generic LLM-based foundation models, InfiniteLife develops its proprietary foundation models as vertical specific foundation models for drug discovery, mainly focusing on Central Nervous Systems (CNS) diseases, such as Parkinson’s and Stroke.
Opening the deck…
Page 1
Best customer profile
- Have you probably thought our ideal customers are big pharmaceutical companies, such as Pfizer, Merck or Johnson & Johnson? But no, our ideal customers are small to midsized pharmaceutical companies, who are really working on drug discovery. The big pharmaceutical companies have no longer been doing R&D on drug discovery because it’s too risky and too expensive. They are waiting for smaller pharmaceutical companies to successfully finish clinical trial phase 3 to acquire them.
- While drug discovery is too risky and too expensive (averaging 10 years and 2 billion dollars), hundreds of thousands of companies are still doing this. It’s high-risk, high-reward. If you pass clinical trial 3, you are mostly valued at more than a billion dollars. You can IPO even before you start your clinical trial 1.
- InfiniteLife is the platform to accelerate drug discovery, aiming to make it 10x cheaper and 10x faster. If so, when everybody is digging for gold, we provide the shovel business.
Notable paying customers
- When considering LIFE AI as a whole, we generated more than $10M in revenue, partnering with more than 100 corporations, including 30+ hospitals and research institutions. InfiniteLife has not had its customer yet. The moment InfiniteLife has a paying customer, LIFE AI is guaranteed to get its unicorn status.
InfiniteLife is the AI department of LIFE AI. In particular, If you consider LIFE AI as Google, then InfiniteLife is the Google Deepmind department. LIFE AI has been in operation for more than 8 years. Its output provides the infrastructure for InfiniteLife to work. In particular, LIFE AI built and operated the SEA’s largest genomic center, under the brand name Genetica, which also served more than one hundred of thousand users. This helped InfiniteLife to build its proprietary knowledge graph, the core component of InfiniteLife’s technology. The more we look at this, the more we see that Genetica is like Google’s Search and Ads, that serves end-users and generates revenue for Google, while nurturing Google Deepmind for many years.
GenAI Fund portfolio